TAK 573

Drug Profile

TAK 573

Alternative Names: TAK-573; TEV-48573

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antibodies; Antineoplastics; Interferons
  • Mechanism of Action CD38 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 09 Oct 2017 Phase-I/II clinical trials in Multiple myeloma (Monotherapy, Second-line treatment or greator) in USA (IV) (NCT03215030)
  • 11 Jul 2017 Millennium Pharmaceuticals plans a phase I/IIa trial in Multiple myeloma (Second-line therapy or greater, Monotherapy) in USA (IV, Infusion) (NCT03215030)
  • 11 Jul 2017 Preclinical trials in Multiple myeloma in USA (IV) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top